26.24

0.15% -0.04

Pre-market: 27.00 0.76 +2.90%

Amphastar Pharmaceuticals Inc (AMPH)

Overview News Price History Option Chain Financials Why AMPH Down? Discussions Forecast

Amphastar Pharmaceuticals Inc stock is traded at $26.24, with a volume of 466.48K. It is down -0.15% in the last 24 hours and down -17.33% over the past month. Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment pharmaceutical products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.

Previous Close:

$26.28

Open:

$26.34

24h Volume:

466.48K

Relative Volume:

0.81

Market Cap:

$1.25B

Revenue:

$723.55M

Net Income/Loss:

$157.72M

P/E Ratio:

8.7467

EPS:

Net Cash Flow:

$170.15M

1W Performance:

-7.34%

1M Performance:

-17.33%

6M Performance:

-45.44%

1Y Performance:

-39.75%

1-Day Range:

$25.89

$26.86

1-Week Range:

$25.89

$29.37

52-Week Range:

$25.89

$53.95

Amphastar Pharmaceuticals Inc Stock (AMPH) Company Profile

Name

Amphastar Pharmaceuticals Inc

Sector

Healthcare (1169)

Industry

Drug Manufacturers - Specialty & Generic (1)

Phone

909-980-9484

Address

11570 SIXTH STREET, RANCHO CUCAMONGA, CA

Employee

2,028

Twitter

Next Earnings Date

2024-12-06

Latest SEC Filings

AMPH's Discussions on Twitter

Compare AMPH with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AMPH Amphastar Pharmaceuticals Inc	26.24	1.25B	723.55M	157.72M	170.15M	3.00
ZTS Zoetis Inc	160.06	71.67B	9.26B	2.49B	2.30B	5.47
TAK Takeda Pharmaceutical Co Adr	15.03	47.44B	30.25B	1.37B	5.08B	0.4257
HLN Haleon Plc Adr	10.19	46.08B	14.35B	1.85B	0	0.4023
TEVA Teva Pharmaceutical Industries Ltd Adr	16.46	18.86B	16.54B	-1.64B	749.00M	-1.45
ITCI Intra Cellular Therapies Inc	131.36	13.97B	612.78M	-86.37M	-62.91M	-0.87

Amphastar Pharmaceuticals Inc Stock (AMPH) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-04-25	Downgrade	Piper Sandler	Overweight → Neutral
Nov-22-24	Initiated	Wells Fargo	Equal Weight
Mar-05-24	Initiated	JP Morgan	Overweight
Nov-17-23	Initiated	BofA Securities	Neutral
Jul-25-23	Resumed	Jefferies	Buy
Oct-21-22	Resumed	Jefferies	Buy
Jul-29-22	Initiated	CapitalOne	Overweight
Jan-07-22	Upgrade	Piper Sandler	Neutral → Overweight
Jan-08-21	Downgrade	Wells Fargo	Overweight → Equal Weight
Oct-05-20	Upgrade	Northland Capital	Market Perform → Outperform
May-01-20	Initiated	Northland Capital	Outperform
Mar-13-19	Downgrade	Needham	Buy → Hold
Mar-13-19	Downgrade	Piper Jaffray	Overweight → Neutral
Aug-10-18	Reiterated	Needham	Buy
Mar-13-18	Reiterated	Needham	Buy
Dec-01-17	Reiterated	Needham	Buy
Nov-09-17	Downgrade	Raymond James	Outperform → Mkt Perform
Sep-27-17	Reiterated	Needham	Buy
Mar-14-17	Downgrade	Raymond James	Strong Buy → Outperform
Aug-09-16	Reiterated	Needham	Buy
May-10-16	Reiterated	Needham	Buy
Feb-19-16	Initiated	Wells Fargo	Outperform
Jun-19-15	Reiterated	Needham	Buy
Jun-03-15	Initiated	Raymond James	Strong Buy
Jul-21-14	Initiated	Needham	Buy

View All

Amphastar Pharmaceuticals Inc Stock (AMPH) Latest News

Mar 13, 2025

Amphastar Pharmaceuticals (NASDAQ:AMPH) Hits New 1-Year LowShould You Sell? - MarketBeat

Mar 13, 2025

Smartleaf Asset Management LLC Increases Stock Position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - Defense World

Mar 13, 2025

Wealthfront Advisers LLC Buys Shares of 249,605 Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - MarketBeat

Mar 13, 2025

Q4 Earnings Highs And Lows: Amphastar Pharmaceuticals (NASDAQ:AMPH) Vs The Rest Of The Generic Pharmaceuticals Stocks - Yahoo Finance

Mar 13, 2025

Q4 Earnings Highs And Lows: Amphastar Pharmaceuticals (NASDAQ:AMPH) Vs The Rest Of The Generic Pharmaceuticals Stocks | FinancialContent - Financial Content

Mar 13, 2025

Amphastar stock hits 52-week low at $26.97 amid market challenges - Investing.com Australia

Mar 13, 2025

Mar 12, 2025

Amphastar at Barclays Conference: Strategic Focus on Growth and Innovation By Investing.com - Investing.com UK

Mar 12, 2025

Mar 10, 2025

Insider Selling: Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) CFO Sells 4,231 Shares of Stock - MarketBeat

Mar 10, 2025

Mar 08, 2025

Amphastar Pharmaceuticals Inc to Host Earnings Call - ACCESS Newswire

Mar 08, 2025

(AMPH) Proactive Strategies - Stock Traders Daily

Mar 08, 2025

Mar 07, 2025

Amphastar Pharmaceuticals director Petersen sells $27,986 in stock By Investing.com - Investing.com South Africa

Mar 07, 2025

Amphastar Pharmaceuticals director Petersen sells $27,986 in stock - Investing.com India

Mar 07, 2025

Amphastar Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire

Mar 07, 2025

Amphastar Pharmaceuticals CFO sells $116,515 in stock By Investing.com - Investing.com Australia

Mar 07, 2025

Mar 06, 2025

Amphastar Pharmaceuticals CFO sells $116,515 in stock - Investing.com

Mar 06, 2025

Mar 05, 2025

Amphastar Pharmaceuticals to Present at the Barclays 27th Annual Global Healthcare Conference - ACCESS Newswire

Mar 05, 2025

Will Amphastar Reveal New Strategic Insights at Upcoming Barclays Healthcare Conference? - StockTitan

Mar 05, 2025

17,049 Shares in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Purchased by Illumine Investment Management LLC - MarketBeat

Mar 05, 2025

Mar 04, 2025

Amphastar Pharmaceuticals (NASDAQ:AMPH) Sets New 52-Week LowHere's What Happened - MarketBeat

Mar 04, 2025

Amphastar Pharmaceuticals, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud AllegationsAMPH - ACCESS Newswire

Mar 04, 2025

Amphastar’s Earnings Call: Growth Amid Challenges - TipRanks

Mar 04, 2025

Amphastar Pharmaceuticals (NASDAQ:AMPH) Issues Quarterly Earnings Results - MarketBeat

Mar 04, 2025

Mar 03, 2025

AMPH ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Amphastar Pharmaceuticals, Inc. Shareholders Who Lost Money - accessnewswire.com

Mar 03, 2025

Bronchial Spasms Market Expected to rise, 2032 | - openPR

Mar 03, 2025

Mar 02, 2025

Amphastar stock hits 52-week low at $30.32 amid market shifts - Investing.com Australia

Mar 02, 2025

Rhumbline Advisers Buys 1,213 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - Defense World

Mar 02, 2025

D.A. Davidson & CO. Makes New $417,000 Investment in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - MarketBeat

Mar 02, 2025

Mar 01, 2025

Amphastar Pharmaceuticals Full Year 2024 Earnings: EPS Misses Expectations - Yahoo Finance

Mar 01, 2025

Is Amphastar Pharmaceuticals, Inc. (AMPH) the Best Small Cap Pharma Stocks to Buy Now? - Insider Monkey

Mar 01, 2025

Amphastar Pharmaceuticals to Present at the Jefferies Healthcare Conference - ACCESS Newswire

Mar 01, 2025

Feb 28, 2025

Allspring Global Investments Holdings LLC Sells 10,199 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) - MarketBeat

Feb 28, 2025

Primatene Mist Sales Key To Amphastar Growth - Citeline News & Insights

Feb 28, 2025

Specialty Pharma Amphastar Stock Falls On Lower Than Expected Q4 Earnings, Analyst Sees Competitive Headwinds - AOL

Feb 28, 2025